Trial Profile

A Phase I Dose-Escalation Study of Oral ABT-888 (NSC 737664) Plus Intravenous Irinotecan (CPT-11, NSC 616348) Administered in Patients With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Irinotecan (Primary) ; Veliparib (Primary)
Indications Advanced breast cancer; Colon cancer; Hodgkin's disease; Lung cancer; Male breast cancer; Non-Hodgkin's lymphoma; Ovarian cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions

Most Recent Events

15 Apr 2025 Status changed from active, no longer recruiting to completed.
27 Jul 2022 Planned End Date changed from 30 Jun 2022 to 30 Jun 2023.
27 Jul 2022 Planned primary completion date changed from 30 Jun 2022 to 30 Jun 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com